New oncology program identifies VEGFR-3 as a promising cancer target using real-world data and Bioptic’s AI-driven molecule discovery engine.
We’re excited to announce a new strategic partnership between Bioptic and Oncobox, aimed at developing next-generation targeted therapies for cancer. This collaboration marks a major milestone in our shared mission to bring precision medicine closer to patients by uniting cutting-edge data science with real-world clinical insights.
The Discovery: A New Target Emerges
Oncobox, leveraging patient-derived multi-omic data, identified VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3) as a promising therapeutic target for multiple hard-to-treat cancers. These include papillary thyroid, clear-cell renal, pancreatic, ovarian cancers, and sarcomas. Inhibiting this receptor may open the door to more effective, personalized cancer treatments.
Bioptic’s Role: AI-Powered Molecule Discovery
Once the target was identified, Bioptic’s AI algorithms took the lead. Our small molecule binding affinity prediction models — trained on massive biochemical datasets — screened billions of compounds to discover novel inhibitors for VEGFR-3. In just weeks, we identified a dozen highly selective candidates. The most potent showed an IC50 of just 420 nM — a strong foundation for future optimization and development.
This success is a powerful validation of Bioptic’s platform: a target-agnostic engine capable of accelerating drug discovery from hit identification to lead generation, using only a disease signal and the right data.
What’s Next?
This program is just the beginning. We are applying our platform across multiple therapeutic areas and with more partners who are bringing unique data to the table.
If you’re attending any biotech conferences this season, come meet us. We’d love to share more about how we’re turning difficult biology into actionable discoveries with speed and scale.
